1. Home
  2. MIRM vs FICO Comparison

MIRM vs FICO Comparison

Compare MIRM & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.54

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$1,747.45

Market Cap

41.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
FICO
Founded
2018
1956
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
41.2B
IPO Year
2019
1987

Fundamental Metrics

Financial Performance
Metric
MIRM
FICO
Price
$78.54
$1,747.45
Analyst Decision
Strong Buy
Buy
Analyst Count
11
12
Target Price
$92.45
$1,999.83
AVG Volume (30 Days)
831.6K
185.3K
Earning Date
11-04-2025
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.78
EPS
N/A
26.54
Revenue
$471,794,000.00
$1,990,869,000.00
Revenue This Year
$53.78
$24.52
Revenue Next Year
$19.91
$16.94
P/E Ratio
N/A
$66.76
Revenue Growth
53.66
15.91
52 Week Low
$36.88
$1,300.00
52 Week High
$82.58
$2,217.60

Technical Indicators

Market Signals
Indicator
MIRM
FICO
Relative Strength Index (RSI) 60.79 48.82
Support Level $77.99 $1,701.49
Resistance Level $82.58 $1,779.01
Average True Range (ATR) 3.27 43.89
MACD 1.22 -6.47
Stochastic Oscillator 79.12 29.20

Price Performance

Historical Comparison
MIRM
FICO

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

Share on Social Networks: